All In Biotech

Drug Trial Radar · NCT04330300

Coronavirus (COVID-19) ACEi/ARB Investigation

The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jun 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingRandomized with 2,414 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

2,414

Planned (sponsor's estimate)

Start

Apr 30, 2020

Primary completion

Jul 31, 2021

Study completion Dec 1, 2021

Sponsor

Lead sponsor
National University of Ireland, Galway, IrelandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is known to require the angiotensin-converting enzyme 2 (ACE-2) receptor for uptake into the human body, there have been questions about whether medications that upregulate ACE-2 receptors might increase the risk of infection and subsequent complications. One such group of medications are anti-hypertensives that block the renin-angiotensin system, including both angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB). Both ACEi and ARB are widely used for the treatment of hypertension. Early reports from China and Italy suggest that many of those who die from COVID-19 have a coexisting history of hypertension. Consequently, there have been questions raised as to whether these 2 types of blood pressure medication might increase the risk of death among patients with COVID-19. However, it is well known that the prevalence of hypertension increases linearly with age. Therefore, it is possible that the high prevalence of hypertension and ACEi/ARB use among persons who die from COVID-19 is simply confounded by age (older people are at risk of both a history of hypertension and dying from COVID-19). Whether these commonly prescribed blood pressure medications increase the risk of COVID-19 or not remains unanswered. Statements from professional cardiology societies on both sides of the Atlantic have called for urgent research into this question. Our study aims to randomize patients with primary (essential) hypertension who are already taking ACEi/ARB to either switch to an alternative BP medication or continue with the ACEi/ARB that they have already been prescribed. Adults with compelling indications for ACEi/ARB will not be enrolled.

Conditions

  • Hypertension
  • COVID-19

Interventions

  • Thiazide or Thiazide-like diureticsDrug

    Anti-hypertensive (Active Arm)

  • Calcium Channel BlockersDrug

    Anti-hypertensive (Active Arm)

  • ACE inhibitorDrug

    Anti-hypertensive (Control Arm)

  • Angiotensin receptor blockerDrug

    Anti-hypertensive (Control Arm)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Galway

    Galway, Ireland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.